

Supporting information:

## Multivalent aptamer-modified tetrahedral DNA nanocage demonstrates high selectivity and safety for anti-tumor therapy

*Xiu Han*<sup>1,‡</sup>, *Yujie Jiang*<sup>1,‡</sup>, *Shuyi Li*<sup>1</sup>, *Yu Zhang*<sup>1</sup>, *Xiaonan Ma*<sup>2</sup>, *Ziheng Wu*<sup>3</sup>, *Zhenghong Wu*<sup>1,\*</sup>, *Xiaole Qi*<sup>1,\*</sup>

<sup>1</sup>Key Laboratory of Modern Chinese Medicines, China Pharmaceutical University, Nanjing 210009, PR China.

<sup>2</sup>Cellular and Molecular Biology Center, China Pharmaceutical University, Nanjing 210009, PR China.

<sup>3</sup>Jiangning Campus, High School Affiliated to Nanjing Normal University, Nanjing 211102, PR China.

\*Corresponding author: Zhenghong Wu, Xiaole Qi; E-mail address: zhenghongwu66@cpu.edu.cn; qixiaole523@cpu.edu.cn

Tel: +008615062208341; Fax: +0086-025-83179703

‡ Xiu Han and Yujie Jiang contributed equally to this work.


**Table S1.** DNA sequences.

| Strands | DNA sequences                                                                                               |
|---------|-------------------------------------------------------------------------------------------------------------|
| A       | 5-CGTATCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAAATTTATCACCCGCCATAGTAG-3                                          |
| B       | 5-CGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTTCGACATGCGAGGGTCCAATACCG-3                                         |
| C       | 5-GTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCCATCCACTACTATGGCGGGTGATAAA-3                                          |
| D       | 5-CTCAACTGCCTGGTGATACGAGGTGGGCATGCTCTTCCCGACGGTATTGGACCCTCGCATG-3                                           |
| D-Cy5   | 5-CTCAACTGCCTGGTGATACGAGGTGGGCATGCTCTTCCCGACGGTATTGGACCCTCGCATG-Cy5                                         |
| A'      | 5-<br>CGTATCACCAGGCAGTTGAGACGAACATTCCTAAGTCTGAAATTTATACCCGCCATAGTAGTTTTTTTGCAGTTG<br>ATCCTTTGGATACCCTGG-3   |
| B'      | 5-<br>CGATTACAGCTTGCTACACGATTCAGACTTAGGAATGTTTCGACATGCGAGGGTCCAATACCGTTTTTTTGCAGTT<br>GATCCTTTGGATACCCTGG-3 |
| C'      | 5-                                                                                                          |


---

CGTGTAGCAAGCTGTAATCGACGGGAAGAGCATGCCCATCCACTACTATGGCGGGTGATAAATTTTTTGCAGT  
 TGATCCTTTGGATACCCTGG-3

---




**Figure S1.** (A) Non-denaturing PAGE and (B) AGE analysis of the stability of 3apt-Td nanostructure. Totally complementary DNA duplex (strand D+d) and 3apt-Td nanostructure were incubated in 10% non-heat inactivated FBS, 100% non-heat inactivated FBS and 100% murine plasma at 37 °C for 2-12 h and then analyzed with gel electrophoresis.




**Figure S2.** AGE gel (12%) shift assay (A) of B' strand containing aptamer sequence (B-7T-apt) incubated with the MUC1 peptide. These strip indicated B' strand, B' strand incubated with MUC1, B' strand incubated with BSA, d strand (DNA strand complementary with D strand) with


MUC1 and d strand. The flow cytometry ananlysis (B) and the mean fluorescence intensity (MFI; C) of MCF-7 and LO2 cells after incubation with the fluorescently labelled B' stand for 5 h. Data are shown as the mean  $\pm$  SD (n = 3). \*\* indicates  $p < 0.01$  versus MCF-7 cells.




**Figure S3.** The cellular uptake of B' stand containing aptamer sequence (B-7T-apt) in MCF-7, LO2 cells and co-incubation cells after 5 h analyzed by confocal laser scanning microscopy.



**Figure S4.** *In vitro* cytotoxicity assay of 3apt-Td against MCF-7(A) and LO2 cell lines (B) over 48 h.




**Figure S5.** *In vitro* drug release profiles: Dox@Td and free Dox in PBS buffers with various pH values. Data are shown as the mean  $\pm$  SD (n = 3).



**Figure S6.** Quantification of DOX signal for the fluorescence microscopy images in MCF-7 tumor-bearing nude mice after intravenous injection of Dox (control) and Dox@3apt-Td.





**Figure S7.** Histological changes of tumors dissected from nude mice bearing MCF-7 breast tumors treated with saline, 3apt-Td, free Dox and Dox@3apt-Td (Dox dose = 2 mg/kg). Histological analysis was performed via H&E staining, and the images were observed by optical microscopy (Olympus, 400 $\times$ ).

**Table S2.** Effects of Dox on WBC count and spleen indices of MCF-7 tumor-bearing nude mice.

| Groups      | WBC count $\times 10^9(\text{L}^{-1})$ | Spleen index (mg/g) |
|-------------|----------------------------------------|---------------------|
| Saline      | $3.67 \pm 0.15$                        | $0.73 \pm 0.11$     |
| Dox         | $2.07 \pm 0.57^*$                      | $0.60 \pm 0.03^*$   |
| 3apt-Td     | $2.52 \pm 0.87$                        | $0.71 \pm 0.09$     |
| Dox@3apt-Td | $2.70 \pm 0.98$                        | $0.73 \pm 0.12$     |

**Table S3** The influence of the feeding molar ratio of 3apt-Td to Dox on the encapsulation efficiency (EE) and the number of Dox loaded in per 3apt-Td (n = 3).

| Feeding molar ratio of 3apt-Td:Dox | EE (%)       | Number of Dox loaded in per 3apt-Td |
|------------------------------------|--------------|-------------------------------------|
| 1 : 25                             | 83.52 ± 8.12 | 20.88 ± 2.03                        |
| 1 : 50                             | 80.94 ± 5.26 | 40.47 ± 2.63                        |
| 1 : 75                             | 71.55 ± 4.71 | 53.66 ± 3.53                        |
| 1 : 100                            | 55.99 ± 7.88 | 55.99 ± 7.88                        |